Bristol Myers Squibb announced that the European Commission has expanded approval of Reblozyl to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes. This approval of Reblozyl covers all EU member states.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
- Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024
- Bristol Myers ends collaboration agreement with Molecular Templates
- Bristol Myers Squibb (NYSE:BMY) Slips after Disappointing Drug Trial
- Bristol Myers says KRYSTAL-12 trial met primary endpoint in PFS
